Immunotherapy Advances for Epithelial Ovarian Cancer
New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the exi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/12/3733 |
| _version_ | 1797544981082144768 |
|---|---|
| author | Erin G. Hartnett Julia Knight Mackenzy Radolec Ronald J. Buckanovich Robert P. Edwards Anda M. Vlad |
| author_facet | Erin G. Hartnett Julia Knight Mackenzy Radolec Ronald J. Buckanovich Robert P. Edwards Anda M. Vlad |
| author_sort | Erin G. Hartnett |
| collection | DOAJ |
| description | New treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials. |
| first_indexed | 2024-03-10T14:08:13Z |
| format | Article |
| id | doaj.art-d5b5e4bd312d41b79ea716ac6d5034e9 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T14:08:13Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d5b5e4bd312d41b79ea716ac6d5034e92023-11-21T00:28:13ZengMDPI AGCancers2072-66942020-12-011212373310.3390/cancers12123733Immunotherapy Advances for Epithelial Ovarian CancerErin G. Hartnett0Julia Knight1Mackenzy Radolec2Ronald J. Buckanovich3Robert P. Edwards4Anda M. Vlad5Department of Obstetrics and Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USASchool of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USADepartment of Obstetrics and Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USADepartment of Obstetrics and Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USADepartment of Obstetrics and Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USADepartment of Obstetrics and Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation and Magee-Womens Hospital of UPMC, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USANew treatment modalities are needed in order to improve the prognosis of women diagnosed with epithelial ovarian cancer (EOC), the most aggressive gynecologic cancer type. Most ovarian tumors are infiltrated by immune effector cells, providing the rationale for targeted approaches that boost the existing or trigger new anti-tumor immune mechanisms. The field of immuno-oncology has experienced remarkable progress in recent years, although the results seen with single agent immunotherapies in several categories of solid tumors have yet to extend to ovarian cancer. The challenge remains to determine what treatment combinations are most suitable for this disease and which patients are likely to benefit and to identify how immunotherapy should be incorporated into EOC standard of care. We review here some of the most promising immune therapies for EOC and focus on those currently tested in clinical trials.https://www.mdpi.com/2072-6694/12/12/3733epithelial ovarian cancerimmune therapycancer vaccinesimmune checkpoint inhibitorsCAR T cellsoncolytic viruses |
| spellingShingle | Erin G. Hartnett Julia Knight Mackenzy Radolec Ronald J. Buckanovich Robert P. Edwards Anda M. Vlad Immunotherapy Advances for Epithelial Ovarian Cancer Cancers epithelial ovarian cancer immune therapy cancer vaccines immune checkpoint inhibitors CAR T cells oncolytic viruses |
| title | Immunotherapy Advances for Epithelial Ovarian Cancer |
| title_full | Immunotherapy Advances for Epithelial Ovarian Cancer |
| title_fullStr | Immunotherapy Advances for Epithelial Ovarian Cancer |
| title_full_unstemmed | Immunotherapy Advances for Epithelial Ovarian Cancer |
| title_short | Immunotherapy Advances for Epithelial Ovarian Cancer |
| title_sort | immunotherapy advances for epithelial ovarian cancer |
| topic | epithelial ovarian cancer immune therapy cancer vaccines immune checkpoint inhibitors CAR T cells oncolytic viruses |
| url | https://www.mdpi.com/2072-6694/12/12/3733 |
| work_keys_str_mv | AT eringhartnett immunotherapyadvancesforepithelialovariancancer AT juliaknight immunotherapyadvancesforepithelialovariancancer AT mackenzyradolec immunotherapyadvancesforepithelialovariancancer AT ronaldjbuckanovich immunotherapyadvancesforepithelialovariancancer AT robertpedwards immunotherapyadvancesforepithelialovariancancer AT andamvlad immunotherapyadvancesforepithelialovariancancer |